ETFsChiNext 50 Capped Index USD NTR
Invesco

Invesco ChiNext 50 UCITS ETF Acc

CNFY XETRAIrelandNot PEA-eligible
Last close · EUR
7.56EUR
-0.26% · -€0.02
Published closes: 4 Nov 2026 - 5 Nov 2026
5 Nov 2026, close
CNFYBase
Fund charges
0.49%PRIIPs ongoing costs
Fund size
€128.4Mall share classes
Return 1Y
-10.7%
Sharpe 3Y
Not published
Volatility 1Y
34.4%annualised
Holdings
48Fund holdings

Performance

Compare
  • CNFY-10.7%
  • Price, EUR

Returns

Returns1M3M6MYTD1Y3Y5Y
CNFY-16.8%-23.3%-27.0%-12.2%-10.7%--
MSCI World-2.8%-0.6%+7.8%+14.0%+14.1%+65.6%+64.8%
Gap to MSCI World-14.0%-22.7%-34.8%-26.2%-24.8%--

Risk and return

Sharpe ratio · 1Y
-0.35
Below MSCI World · 1.28
Return p.a.
-14.9%
Volatility
34.4%
Max loss
-43.4%Oct 2026

Sharpe vs indices

MSCI World
1.28
S&P 500
1.16
STOXX Europe 600
0.99
MSCI Emerging Markets IMI
0.76
CAC 40
-0.01
CNFY
-0.35
Method

Weekly EUR returns from adjusted closes. Sharpe is the annualised excess return over the euro overnight rate (Xtrackers II EUR Overnight Rate Swap UCITS ETF 1C) divided by its volatility. Max loss uses daily closes.

Top holdings

Top 10
47.2%
Holdings
48
As of
Fund holdings
  1. 1CONTEMPORARY AMPEREX TECHN-A CNY 1.0000CNE1000036627.74%
  2. 2EAST MONEY INFORMATION CO-A CNY 1.0000CNE100000MD47.38%
  3. 3ZHONGJI INNOLIGHT CO LTD-A CNY 1.0000CNE100001CY96.61%
  4. 4EOPTOLINK TECHNOLOGY INC L-A CNY 1.0000CNE1000026155.22%
  5. 5SHENZHEN INOVANCE TECHNOLO-A CNY 1.0000CNE100000V464.11%
  6. 6SHENZHEN MINDRAY BIO-MEDIC-A CNY 1.0000CNE100003G673.79%
  7. 7SUNGROW POWER SUPPLY CO LT-A CNY 1.0000CNE1000018M73.58%
  8. 8CHAOZHOU THREE-CIRCLE GROU-A CNY 1.0000CNE100001Y423.25%
  9. 9HANGZHOU CHANG CHUAN TECHN-A CNY 1.0000CNE100002Q092.76%
  10. 10VICTORY GIANT TECHNOLOGY -A CNY 1.0000CNE1000020V42.75%

Countries

Not published · Country classification unavailable

Market cap

Weight vs holdings

47.2%of the fund sits in the top 10 holdings
  • Holdings 1-10
  • Holdings 11-48

Size split

Not published

Compare ETFs in Copio.

ETF comparison in the Copio app, showing costs and returns with illustrative data.

Factual research, without a suitability score or investment recommendation. Past relationships can change.